Clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases.
Clinical-stage biotechnology company advancing a next-generation protein degradation pipeline and platform that targets extracellular membrane and soluble proteins.
Clinical-stage biotechnology company working to develop potent and versatile tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins.
Clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases.
Clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
Clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders.
Completed IPO in 2025
Global HealthTech company that connects patients, physicians, trial sites, and BioPharma partners to enable earlier and better access to pre-approval treatments.
Clinical-stage biotechnology company discovering and developing novel therapies to treat immune-mediated chronic inflammatory diseases.
Completed IPO in 2025
Clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis.
Clinical-stage biotechnology company developing purpose-built therapeutics by leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology.
A full-service, digitally-powered pharmacy providing an easier, more supportive and more affordable pharmacy experience.
Commercial-stage life science company focused on manufacturing scalable single-use bioreactors and providing process development services to cell therapy clients.
Global contract development and manufacturing organization for radiotherapeutics.
Health prediction company utilizing proteomics and advanced statistical techniques to better predict and improve health outcomes.
Commercial-stage life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing.
Clinical-stage biotechnology company focused on enabling cures with hematopoietic stem cell therapies.
Merged with Amplitude Healthcare Acquisition Corporation in 2021
Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Completed IPO in 2021
Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.
Completed IPO in 2021
Commercial-stage specialty pharmaceutical company focused on gastrointestinal, dermatological, and women’s health products.
Clinical-stage therapeutics company focused on the central nervous system (CNS), orphan diseases, and conditions with high unmet medical need.
FOR VELAN HOLDINGS PLEASE SEE OUR 13F FILINGS.